Becton, Dickinson and Company (NYSE:BDX)‘s stock had its “buy” rating restated by research analysts at Stifel Nicolaus in a report issued on Friday. They currently have a $245.00 price objective on the medical instruments supplier’s stock. Stifel Nicolaus’ price target would indicate a potential upside of 9.18% from the company’s current price.

Other analysts have also issued reports about the company. BidaskClub lowered Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Bank of America Corporation reaffirmed a “buy” rating and issued a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a research note on Monday, July 17th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a research note on Monday, August 14th. Five investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Becton, Dickinson and has an average rating of “Buy” and an average price target of $211.94.

Shares of Becton, Dickinson and (NYSE BDX) traded up $16.35 during midday trading on Friday, hitting $224.41. The company had a trading volume of 958,312 shares, compared to its average volume of 1,325,794. The company has a market cap of $50.98 billion, a P/E ratio of 23.61 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating the consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.14 billion. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. Becton, Dickinson and’s revenue was down 2.0% compared to the same quarter last year. During the same period last year, the firm posted $2.12 earnings per share. analysts predict that Becton, Dickinson and will post 10.65 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Becton, Dickinson and Company (BDX) Given Buy Rating at Stifel Nicolaus” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/03/becton-dickinson-and-company-bdx-given-buy-rating-at-stifel-nicolaus.html.

In related news, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the transaction, the insider now directly owns 26,638 shares of the company’s stock, valued at $5,279,917.98. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The disclosure for this sale can be found here. Insiders have sold 75,904 shares of company stock worth $15,242,688 over the last three months. Insiders own 1.40% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. Guardian Life Insurance Co. of America lifted its stake in shares of Becton, Dickinson and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after acquiring an additional 6 shares during the period. Family Firm Inc. lifted its stake in shares of Becton, Dickinson and by 0.5% in the second quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock worth $236,000 after acquiring an additional 6 shares during the period. Northwest Quadrant Wealth Management LLC lifted its stake in shares of Becton, Dickinson and by 0.4% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock worth $332,000 after acquiring an additional 6 shares during the period. Wellington Shields & Co. LLC lifted its stake in shares of Becton, Dickinson and by 0.3% in the second quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock worth $496,000 after acquiring an additional 7 shares during the period. Finally, Northstar Group Inc. lifted its stake in shares of Becton, Dickinson and by 0.3% in the second quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock worth $584,000 after acquiring an additional 9 shares during the period. 86.70% of the stock is currently owned by institutional investors.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.